Transarterial oily chemoembolization with lidamycin shows potent therapeutic efficacy in VX2 rabbit liver tumor

Zhong G, Qi J, Huo S, Xue H, Xu Z, Li J, Zhou Y, Wu M, Li L
2015 OncoTargets and Therapy  
Genshen Zhong,1,* Jinsong Qi,2,* Shuhua Huo,1 Huichao Xue,3 Zhishan Xu,1 Jinsong Li,4 Yanjun Zhou,5 Minna Wu,1 Liang Li6 1Laboratory of Cancer Biotherapy, Institute of Neurology, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan Province, People's Republic of China; 2Department of Intervention, 3Department of General Surgery, 4Department of Pathology, 5Department of Clinical Laboratory, The First Affiliated Hospital of Xinxiang Medical University, Weihui, Henan
more » ... , People's Republic of China; 6Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People's Republic of China *These authors contributed equally to this work Abstract: Transarterial oily chemoembolization (TOCE) is one of the most effective approaches for the treatment of patients with hepatocellular carcinoma (HCC), who are not suitable for surgical therapy. Lidamycin (LDM), a potent antitumor antibiotic, demonstrates good antitumor efficacy in various tumor types, both in vitro and in vivo. In this study, the antitumor efficacy of LDM combined with TOCE against the rabbit VX2 tumor was assessed. A toxicity assay with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) demonstrated that a combination of LDM with lipiodol did not impair the cytotoxicity of LDM against HepG2 cells in vitro. Using TOCE in rabbit VX2 tumor models, LDM showed a more powerful inhibitory effect against the tumor and lowered the expression levels of proliferating cell nuclear antigen (PCNA), cluster of differentiation 31 (CD31), and vascular endothelial growth factor (VEGF) compared to Adriamycin (ADM); moreover, this improvement was not accompanied by an increase of hepatotoxicity as shown by alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels. These results suggested that LDM combined with TOCE may be a feasible strategy in HCC therapy in the future. Keywords: lidamycin, TOCE, hepatocellular carcinoma, VX2, Adriamycin
doaj:c6c0a0b751f744779ed44abda2d09dec fatcat:igllxalkhbglvdvehfkp7zuj3q